Target：VSIG1

Gene Name：VSIG1 GPA34

Protein Name：V-set and immunoglobulin domain-containing protein 1 (Cell surface A33 antigen) (Glycoprotein A34)

Human Gene Id：340547

Human Swiss Prot No：Q86XK7

Mouse Swiss Prot No：Q9D2J4

Rat Swiss Prot No：Q4KLY3

Immunogen：Synthesized peptide derived from human protein . at AA range: 1-80

Specificity：VSIG1 Polyclonal Antibody detects endogenous levels of protein.

Formulation：Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500-2000 ELISA 1:5000-20000

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Observed Band(KD)：42kD

Background： This gene encodes a member of the junctional adhesion molecule (JAM) family. The encoded protein contains multiple glycosylation sites at the N-terminal region, and multiple phosphorylation sites and glutamic acid/proline (EP) repeats at the C-terminal region. The gene is expressed in normal stomach and testis, as well as in gastric, esophageal and ovarian cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2009],

Function：PTM:Highly N-glycosylated. Appears not to contain significant amounts of O-linked carbohydrates or sialic acid in its sugar moieties.,similarity:Contains 1 Ig-like C2-type (immunoglobulin-like) domain.,similarity:Contains 1 Ig-like V-type (immunoglobulin-like) domain.,tissue specificity:Detected only in stomach mucosa and testis, and to a much lesser lever in pancreas (at protein level). Detected in gastric cancers (31%), esophageal carcinomas (50%) and ovarian cancers (23%).,

Subcellular Location：Membrane ; Single-pass type I membrane protein .

Expression：Detected only in stomach mucosa and testis, and to a much lesser level in pancreas (at protein level). Detected in gastric cancers (31%), esophageal carcinomas (50%) and ovarian cancers (23%).